The Primary Biliary Cholangitis (Primary Biliary Cirrhosis) drugs in development market research report provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued products.
GlobalData tracks 31 drugs in development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) by 30 companies/universities/institutes. The top development phase for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) is preclinical with 11 drugs in that stage. The Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline has 31 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline products market are: Intercept Pharmaceuticals, Xiamen Boruilai Pharmaceutical Technology and Brillian Pharma.
The key targets in the Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline products market include Bile Acid Receptor, Peroxisome Proliferator Activated Receptor Alpha, and Peroxisome Proliferator Activated Receptor Delta.
The key mechanisms of action in the Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline product include Bile Acid Receptor Agonist with eight drugs in Pre-Registration. The Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline products include three routes of administration with the top ROA being Oral and six key molecule types in the Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline products market including Small Molecule, and Synthetic Peptide.
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) overview
Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen, and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.
For a complete picture of Primary Biliary Cholangitis (Primary Biliary Cirrhosis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
